Amneal Pharmaceuticals, Inc. (AMRX) Thursday said that the U.S. Food and Drug Administration (FDA) has approved prednisolone acetate ophthalmic suspension, a generic version of Allergan's Pred Forte.
Prednisolone acetate ophthalmic suspension is indicated for treating steroid-responsive ocular inflammation.
Amneal plans to launch the product in the third quarter of 2025.
According to IQVIA, U.S. annual sales for prednisolone acetate ophthalmic suspension for the 12 months ended April 2025 were about $201 million.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.